ArticleBiopsychosocial science and medicine2026
A Pilot Study of the Real-World Impact of Digital Cognitive Behavioral Therapy for Inflammatory Bowel Disease (COMPASS-IBD) on Inflammation, Disease Activity, and Healthcare Use.
Article in Biopsychosocial science and medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05330299 (Acceptability of Identifying and Managing Psychological Distress in Inflammatory Bowel Disease), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Acceptability of Identifying and Managing Psychological Distress in Inflammatory Bowel Disease: the COMPASS-IBD Study
Who cites it
1 citing paper in PubMed.
- Psychological distress predicts disease activity in inflammatory bowel disease: Results from the mind-body IBD longitudinal study.Brain, behavior, & immunity - health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveInflammatory bowel disease (IBD) is commonly accompanied by psychological distress, which may worsen disease activity through gut-brain axis mechanisms. Psychological interventions including cognitive behavioral therapy (CBT) seem to reduce distress and inflammation in IBD. However, accessibility to psychological care remains limited. COMPASS-IBD, a digital CBT intervention tailored to IBD, aims to address these gaps.This nested exploratory, real-world study (NCT05330299) assessed the effectiveness of COMPASS-IBD in reducing inflammation, disease activity, and health care use in IBD patients. In addition, it examined relationships between changes in psychological distress and disease indicators.
methodsAdults with IBD experiencing psychological distress were recruited from a large gastroenterology service, and enrolled in COMPASS-IBD. Disease-related primary outcomes were faecal calprotectin (FCP), C-reactive protein (CRP), and self-reported disease activity (SRDA). Secondary outcomes included other inflammatory biomarkers (neutrophils, monocytes, lymphocytes, white blood cells (WBC), ferritin, flare frequency, and health care usage. The Patient Health Questionnaire-Anxiety and Depression Scale (PHQ-ADS) measured distress. Mixed-effects models evaluated outcomes at baseline, 12 weeks, and 6 months.
resultsSixty-five participants were included. There were significant reductions in CRP ( d range: -0.47 to -0.53, P <.01), but not FCP ( d range: -0.38 to -0.44, P <.10) or SRDA ( d =-0.28, P =.08). Significant improvements were observed in WBC and neutrophil counts ( P <.05), flare frequency ( P <.01), and psychological distress ( P <.001). Some types of health care usage were reduced ( P <.05). Associations between distress and primary outcomes were nonsignificant.
conclusionsThis pilot suggests COMPASS-IBD may reduce inflammation levels, health care use, and psychological distress. However, analyses were underpowered. Larger randomized trials are needed to confirm findings, establish cost-effectiveness, and explore underlying gut-brain mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.